Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin with alternating XELIRI and XELOX in metastatic colorectal cancer
NCT01531595Phase 2Active, not recruiting
- Start
- Feb 2012
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in colorectal cancer (metastatic) (mCRC). Primary endpoints: Progression-Free Survival at 5 years and Resectability of metastases at 5 years. Started Feb 2012; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01531595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531595.